Resultats globals: 2 registres trobats en 0.02 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
19 p, 1.8 MB Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors : 3-Year Follow-Up (SPIRIT-P2) / Orbai, Ana-Maria (Johns Hopkins University School of Medicine) ; Gratacós, Jordi (Universitat Autònoma de Barcelona. Departament de Medicina) ; Turkiewicz, Anthony (Rheumatology Associates Clinical Research Unit (Birmingham, Estats Units)) ; Hall, Stephen (Monash University) ; Dokoupilova, Eva (Masaryk University. Department of Pharmaceutical Technology, Faculty of Pharmacy) ; Combe, Bernard (CHU Montpellier and Montpellier University) ; Nash, Peter (Griffith University. School of Medicine) ; Gallo, Gaia (Eli Lilly and Company) ; Bertram, Clinton C. (Eli Lilly and Company) ; Gellett, Amanda M. (Eli Lilly and Company) ; Sprabery, Aubrey Trevelin (Eli Lilly and Company) ; Birt, Julie (Eli Lilly and Company) ; Macpherson, Lisa (Eli Lilly and Company) ; Geneus, Vladimir J. (Eli Lilly and Company) ; Constantin, Arnaud (Université Toulouse III)
Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin-17A. The objective of this study was to assess the long-term efficacy and safety (to week 156) of ixekizumab in patients with active psoriatic arthritis and inadequate response or intolerance to one or two tumor necrosis factor inhibitors. [...]
2020 - 10.1007/s40744-020-00261-0
Rheumatology and Therapy, Vol. 8 (march 2021) , p. 199-217  
18 p, 504.6 KB Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis : Results from Greater Than 17,000 Patient-Years of Exposure / Armstrong, April (Keck School of Medicine of the University of Southern California. Department of Clinical Research) ; Paul, Carle (Paul Sabatier University. Dermatology Department, Toulouse University Hospital (CHU)) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Boehncke, Wolf Henning (University of Geneva. Department of Pathology and Immunology) ; Freeman, Michael (The Skin Centre, Benowa, QLD Australia) ; Torii, Hideshi (Tokyo Yamate Medical Center. Division of Dermatology) ; Papp, Kim (K Papp Clinical Research and Probity Medical Research) ; Griffiths, Christopher E. M. (NIHR Manchester Biomedical Research Centre. Dermatology Centre, Salford Royal Hospital, University of Manchester) ; Blauvelt, Andrew (Oregon Medical Research Center) ; Reich, Kristian (Skinflammation® Center, Hamburg, Germany) ; Gooderham, Melinda (Centre for Dermatology and Probity Medical Research, Peterborough, ON Canada) ; Terui, Tadashi (Nihon University School of Medicine. Department of Dermatology) ; Renda, Lisa (Eli Lilly and Company) ; Agada, Noah (Eli Lilly and Company) ; Xu, Wen (Eli Lilly and Company) ; Gallo, Gaia (Eli Lilly and Company) ; Lebwohl, Mark G. (Icahn School of Medicine at Mount Sinai. Department of Dermatology) ; Universitat Autònoma de Barcelona
Long-term safety data are critical for evaluating therapies for psoriasis. Ixekizumab has demonstrated efficacy and is well tolerated for the treatment of moderate-to-severe plaque psoriasis. We examined the safety and tolerability of up to 5 years of ixekizumab therapy in patients with psoriasis. [...]
2019 - 10.1007/s13555-019-00340-3
Dermatology and Therapy, Vol. 10 (november 2019) , p. 133-150  

Vegeu també: autors amb noms similars
2 Gallo, G.
1 Gallo, Giorgio
2 Gallo, Gustavo
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.